Video

Dr. Bahary on Treatment Strategies for Right- Versus Left-Sided Tumors in CRC

Nathan Bahary, MD, PhD, discusses treatment strategies for right- versus left-sided tumors in colorectal cancer.

Nathan Bahary, MD, PhD, associate professor, University of Pittsburgh School of Medicine, medical oncologist and hematologist, University of Pittsburgh Medical Center​ Hillman Cancer Center, discusses treatment strategies for right- versus left-sided tumors in colorectal cancer (CRC).

Patients with right-sided tumors ​tend to have more microsatellite instab​ilty, says Bahary. Typically, ​this is due to methylation of MLH1, which is sensitive to immunotherapy.

Prior to immunotherapy, patients with CRC ​often received EGFR inhibitor​s, such as cetuximab ​(Erbitux) or panitumumab ​(Vectibix), says Bahary. However, past research ​revealed that patients with KRAS, BRAF, orNRAS mutations do not derive benefit from EGFR inhibitors alone. 

Furthermore, in the metastatic setting, ​patients with right-sided tumors do not respond to the combination of chemotherapy and EGFR inhibitors, whereas ​patients with left-sided tumors can respond to such combinations, Bahary explains.

As such, patients with ​metastatic CRC and right-sided tumors ​should receive bevacizumab (Avastin) or anequivalent anti-VEGF agent, Bahary concludes.

Related Videos
Michael R. Bishop, MD
Lori A Leslie, MD
Andrew Ip, MD
Mansi R. Shah, MD
Elizabeth Buchbinder, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Alec Watson, MD
Sagar D. Sardesai, MBBS
Ashkan Emadi, MD, PhD
Matthew J. Baker, PhD